epidoxorubicine, docetaxel, cyclophosphamide — Competitive Intelligence Brief

epidoxorubicine, docetaxel, cyclophosphamide (epidoxorubicine, docetaxel, cyclophosphamide) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: anthracycline antibiotic, taxane, alkylating agent. Area: Oncology.

phase 3 anthracycline antibiotic, taxane, alkylating agent topoisomerase II, microtubules, DNA Oncology Small molecule

Target snapshot

epidoxorubicine, docetaxel, cyclophosphamide (epidoxorubicine, docetaxel, cyclophosphamide) — Sanofi. Epidoxorubicine is an anthracycline antibiotic that intercalates DNA strands, thereby inhibiting the progression of topoisomerase II and inducing apoptosis in cancer cells. Docetaxel is a taxane that stabilizes microtubules, preventing cell division and leading to cell death. Cyclophosphamide is an alkylating agent that adds an alkyl group to DNA, causing cross-linking and DNA damage, which ultimately leads to cell death.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
epidoxorubicine, docetaxel, cyclophosphamide TARGET	epidoxorubicine, docetaxel, cyclophosphamide	Sanofi	phase 3	anthracycline antibiotic, taxane, alkylating agent	topoisomerase II, microtubules, DNA
epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile	epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile	Sanofi	phase 3	anthracycline antibiotic, taxane, alkylating agent, antifolate, thymidylate synthase inhibitor	topoisomerase II, microtubules, dihydrofolate reductase, thymidylate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (anthracycline antibiotic, taxane, alkylating agent class)

1. Sanofi · 1 drug in this class